NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

HemoCue develops point-of-care testing systems like hemoglobin, glucose and others worldwide. The company believes that, in addition to its earlier divestment of OralDNA Labs salivary-diagnostics ...

As per its plan to sell the HemoCue diagnostics products business, Quest Diagnostics (DGX), recently completed the divesture of the same. The company announced that Radiometer Medical ApS purchased ...

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to sell its HemoCue diagnostic products ...

Radiometer Limited, a leading provider of technologically advanced acute care testing solutions, is pleased to announce that following its recent acquisition of HemoCue, the Company will be offering ...

Co announces it has acquired HemoCue, a Swedish co specializing in near patient testing, also known as point-of- care testing, from the private equity firm E.Q.T II B.V. in a cash transaction valued ...

In February 2013, Quest Diagnostics announced it had entered into a definitive agreement to sell HemoCue to Radiometer, with plans to use the proceeds to repurchase approximately $300 million of Quest ...

Danaher’s point-of-care focused HemoCue subsidiary has launched its newest hemoglobin test in the U.S. following a recent 510(k) clearance from the FDA. The company’s Hb 801 system allows healthcare ...

Medical company Quest Diagnostics (DGX 0.90%) announced in a press statement early Monday that it has agreed to sell its HemoCue diagnostics business, a division that makes and markets hemoglobin, ...